Results 31 to 40 of about 80,637 (252)

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

Journal for ImmunoTherapy of Cancer
Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20).Methods Patients with advanced solid tumors who were immune-checkpoint inhibitor ...
Sara Lonardi, Christopher Jackson, R Donald Harvey, Armando Santoro, Iwona Lugowska, José Trigo, Anne O’Donnell, Richard North, Urvi Aras, Loes Maria Latten-Jansen, Linghui Li, Devanand Joseph, Bryan Bennett, Balmeet Gurm, Wee-Teck Ng, Aitana Calvo, Marcelo Garrido, Rastislav Bahleda, Matías Rodrigo Chacon, Heather E Vezina, Deepak Perumal   +20 more
doaj   +1 more source

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Journal for ImmunoTherapy of Cancer, 2019
Background Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown.
Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini   +8 more
doaj   +1 more source

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

BMC Cancer, 2022
Background The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking.
T. Waddell, K. Fife, R. Griffiths, A. Sharma, P. Dhokia, L. Groves, M. Hurst, C. Tsang, D. Sugrue, S. McKenna, J. Houghton, R. Carroll   +11 more
doaj   +1 more source

Nivolumab-induced sensory ganglionopathy

, 2023
Introduction Nivolumab is s a human monoclonal antibody. Due to its widespread use in many cancers, including Merkel cell carcinoma, adverse reactions associated with nivolumab, such as neuropathies, endocrinopathies, gastrointestinal problems, and skin ...
Coşkun, Özlem, Coşkun, Uğur, Selim Yalcin, Yalcin, Selim, Ugur Coskun, Yekta C. Sahin, Hasan Sahin, Şahin, Hasan, Ozlem Coskun, Şahin, Yekta C.   +9 more
core   +1 more source

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047

Journal for ImmunoTherapy of Cancer
Background Treatment-free survival (TFS; time spent free of systemic anticancer therapy) is increasingly used to support traditional endpoints. TFS was previously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab.
Christopher D Lao, Hussein Tawbi, Andriy Moshyk, Meredith M Regan, Jennell Palaia, Abraham Selvan, Ravi Potluri, Sandip Ranjan, Sandeep Bilthare   +8 more
doaj   +1 more source

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

CPT: Pharmacometrics & Systems Pharmacology, 2019
Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal ...
Jason Zhang, Kinjal Sanghavi, Jun Shen, Xiaochen Zhao, Yan Feng, Paul Statkevich, Jennifer Sheng, Amit Roy, Li Zhu   +8 more
doaj   +1 more source

Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune‐related adverse events and favorable outcome

Cancer Medicine, 2023
Introduction Immune‐related adverse events (irAEs) are prognostic factors for patients on nivolumab. However, predictors of irAEs have not yet been identified.
Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii   +7 more
doaj   +1 more source

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Frontiers in Pharmacology, 2022
Objective: Nivolumab improves overall survival (OS) and is associated with fewer adverse events than sorafenib for the treatment of advanced hepatocellular carcinoma (aHCC).
Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, Xiaoyu Chen   +5 more
doaj   +1 more source

Nivolumab Efficacy and Safety in Cancer Patients with Renal Dysfunction [PDF]

Aim: Immune checkpoint inhibitors have transformed cancer treatment; however, clinical trials often exclude patients with renal dysfunction. This study aimed to evaluate the efficacy and safety of nivolumab in this population, addressing the limited ...
Gulcin Sahingoz Erdal, Caner Kapar, Mesut Yilmaz, Ezgi Degerli, Ayse Gul Satman Durmaz, Esra Turan Canbaz, Rumeysa Colak, Deniz Tural   +7 more
core   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source